Literature DB >> 23122394

Characterization and identification of alanine to serine sequence variants in an IgG4 monoclonal antibody produced in mammalian cell lines.

Jinmei Fu1, Jacob Bongers, Li Tao, Dan Huang, Richard Ludwig, Yunping Huang, Yueming Qian, Jonathan Basch, Joel Goldstein, Ramji Krishnan, Li You, Zheng Jian Li, Reb J Russell.   

Abstract

Low levels of alanine to serine sequence variants were identified in an IgG4 monoclonal antibody by ultra/high performance liquid chromatography and tandem mass spectrometry. The levels of the identified sequence variants A183S and A152S, both in the light chain, have been determined to be 7.8-9.9% and 0.5-0.6%, by extracted ion currents of the tryptic peptides L16 and L14, respectively. The A183S variant was confirmed through tryptic map spiking experiments using synthetic peptide, SDYEK, which incorporated Ser at the position of native Ala in the tryptic peptide L16. Both mutations were also observed by endoproteinase Asp-N peptide mapping. The variant level of A183S was also quantified by LC-UV with detection at 280nm and fluorescence detection of tyrosine residues on the tryptic peptides. The results from LC-MS, UV, and fluorescence detection are in close agreement with each other. The levels of the sequence variants are comparable among the antibody samples manufactured at different scales as well as locations, indicating that the variants' levels are not affected by manufacture scale or locations. DNA sequencing of the master cell bank revealed the presence of mixed bases at position 183 encoding both wild and mutated populations, whereas bases encoding the minor sequence variant at position 152 were not detected. The root cause for A152S mutation is not yet clearly understood at this moment.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122394     DOI: 10.1016/j.jchromb.2012.09.023

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Identification and characterization of a -1 reading frameshift in the heavy chain constant region of an IgG1 recombinant monoclonal antibody produced in CHO cells.

Authors:  Zhirui Lian; Qindong Wu; Tongtong Wang
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

2.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

3.  Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.

Authors:  Yantao Li; Tuo Fu; Tao Liu; Huaizu Guo; Qingcheng Guo; Jin Xu; Dapeng Zhang; Weizhu Qian; Jianxin Dai; Bohua Li; Yajun Guo; Sheng Hou; Hao Wang
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

Review 4.  In vitro and in vivo modifications of recombinant and human IgG antibodies.

Authors:  Hongcheng Liu; Gomathinayagam Ponniah; Hui-Min Zhang; Christine Nowak; Alyssa Neill; Nidia Gonzalez-Lopez; Rekha Patel; Guilong Cheng; Adriana Z Kita; Bruce Andrien
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  Design, synthesis, and characterization of BRC4 mutants based on the crystal structure of BRC4-RAD51(191-220).

Authors:  Dongxin Zhao; Kui Lu
Journal:  J Mol Model       Date:  2015-11-02       Impact factor: 1.810

6.  Development of an LC-MS/MS peptide mapping protocol for the NISTmAb.

Authors:  Trina Mouchahoir; John E Schiel
Journal:  Anal Bioanal Chem       Date:  2018-02-07       Impact factor: 4.142

Review 7.  Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics.

Authors:  T Jennifer Lin; Kathryn M Beal; Paul W Brown; Heather S DeGruttola; Mellisa Ly; Wenge Wang; Chia H Chu; Robert L Dufield; Gerald F Casperson; James A Carroll; Olga V Friese; Bruno Figueroa; Lisa A Marzilli; Karin Anderson; Jason C Rouse
Journal:  MAbs       Date:  2018-10-25       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.